MKI67 and breast cancer: Moreover, the proportion of patients with Ki67‐H was higher in patients with PD‐L1‐H in HR+/HER2− cohort (p = 0.001), HR+/HER2− cohort (p = 0.002), HR+ cohort (p = 0.004), HER2+ cohort (p = 0.001), HER2− cohort (p = 0.0003), and all BC patients (p = 0.0006), but were not associated with TMB levels (Figure 5E‐I, Figure S3B, Tables S3 and S4).